A synthetic analog of the immunomodulatory peptide tuftsin, developed in Russia and studied for anxiolytic (anti-anxiety) and cognitive effects, often administered intranasally in research.
Mechanism under study
Research associates Selank with modulation of GABAergic and serotonergic signaling and stabilization of enkephalins and BDNF, contributing to reported anxiolytic and neuroprotective effects.
Research-reported dosing
Research references commonly cite ~250–500 mcg intranasally. Most human data comes from Russian clinical research; it is not FDA-approved.
Based on a standard 10 mg vial: with 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit ≈ 50 mcg.
A 300 mcg dose ≈ 6 units (50 mcg per unit).
Open this mix in the calculator →Source research-grade Selank ↗Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Selank FAQ
What is Selank?
A synthetic analog of the immunomodulatory peptide tuftsin, developed in Russia and studied for anxiolytic (anti-anxiety) and cognitive effects, often administered intranasally in research.
What is the half-life of Selank?
Short in plasma; intranasal administration is common in research.
What is the research-reported dosing for Selank?
Research references commonly cite ~250–500 mcg intranasally. Most human data comes from Russian clinical research; it is not FDA-approved.
How is Selank reconstituted?
Based on a standard 10 mg vial: with 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit ≈ 50 mcg.
Is Selank FDA-approved?
Selank has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.